Publications

Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, Minor DR, DiSaia PJ. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecologic oncology. 2003. PMID: 12504624


Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate cancer and prostatic diseases. 2003. PMID: 14663466


Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003. PMID: 12506177


Lee TT, Everett DL, Shu HK, Jahan TM, Roach M, Speight JL, Cameron RB, Phillips TL, Chan A, Jablons DM. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. The Journal of thoracic and cardiovascular surgery. 2002. PMID: 12447185


Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nature reviews. Cancer. 2002. PMID: 12459730


De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV. Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. British journal of haematology. 2002. PMID: 12437658


Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends in molecular medicine. 2002. PMID: 12470990


Soumelis V, Scott I, Liu YJ, Levy J. Natural type 1 interferon producing cells in HIV infection. Human immunology. 2002. PMID: 12480265


Oh WK, Small EJ. Complementary and alternative therapies in prostate cancer. Seminars in oncology. 2002. PMID: 12516040


Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. Journal of virology. 2002. PMID: 12368346


Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Current opinion in hematology. 2002. PMID: 12394172


Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer control : journal of the Moffitt Cancer Center. 2002. PMID: 12514564


Munster PN. Improving breast cancer care. Cancer control : journal of the Moffitt Cancer Center. 2002. PMID: 12514562


Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco Md, Dale TC, Smalley MJ. Functional and molecular characterisation of mammary side population cells. Breast cancer research : BCR. 2002. PMID: 12559051


Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002. PMID: 12370822


Rini BI, Small EJ. Hormone-refractory Prostate Cancer. Current treatment options in oncology. 2002. PMID: 12194808


Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. PMID: 12351594


Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Current opinion in biotechnology. 2002. PMID: 12459333


Gale M, Blakely CM, Darveau A, Romano PR, Korth MJ, Katze MG. P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress. Biochemistry. 2002. PMID: 12269832


Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. PMID: 12228201